{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:38:38Z","timestamp":1793824718758,"version":"4.6.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G0B9819N"],"award-info":[{"award-number":["G0B9819N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Although some jurisdictions have implemented particular adjustments to accommodate often-expensive orphan drugs in their healthcare systems, availability of these drugs remains complex. This study investigates alternative financing models and early access schemes for orphan drugs in the context of the Belgian healthcare system.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Three focus group discussions were held with a panel of eleven experts from the Belgian Drug Reimbursement Committee, the Colleges for Orphan Drugs, the pharmaceutical industry, physicians, ethicists and pharmacists. Retrieved data were pseudonymised, analysed and coded according to the Qualitative Analysis Guide of Leuven.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Experts disfavoured the insulated fund as well as private insurance for financing orphan drugs, as, respectively, isolation of a separate budget and a mostly profit-driven mechanism would contradict the Belgian fundamental principle of solidarity. Moreover, an insulated fund could, albeit on a smaller scale, reproduce the same budgetary constraints as the general reimbursement system. As the Special Solidarity Fund is intended for urgent care and exclusively accommodates financial needs subject to eligibility criteria, its design would not allow general financing of orphan drugs. Overall, implementation of an alternative financing model was not endorsed, instead, improving the current reimbursement system was preferred. Suggestions mentioned were; increased collaboration and transparency, robust and quality real-world evidence but also digitalization of data. Alleviating administrative burden and simplifying the admission process of compassionate use program, medical need program and early treatment reimbursement should be prioritized to facilitate early access. Furthermore, a legal framework for off-label use could stimulate proper implementation. Efforts on collaboration of expertise centres and coordination of orphan drug databases across Europe could foster a robust data network to support orphan drug availability in individual countries.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This research reveals that reassessing current financing models and early access schemes by eliminating inadequacies, may be more conducive than establishing alternative systems to increase availability of orphan drugs in Belgium. Other jurisdictions may rely on this information to review their own models of early access and financing to cultivate a more sustainable delivery of orphan drugs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02571-8","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T09:03:14Z","timestamp":1670576594000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Exploring alternative financing models and early access schemes for orphan drugs: a Belgian case study"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0149-9213","authenticated-orcid":false,"given":"Khadidja","family":"Abdallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Claes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Huys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennert","family":"Follon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Calis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Simoens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"1","key":"2571_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13023-017-0601-9","volume":"12","author":"L Annemans","year":"2017","unstructured":"Annemans L, Ayme S, Le Cam Y, Facey K, Gunther P, Nicod E, et al. Recommendations from the European working group for value assessment and funding processes in rare diseases (ORPH-VAL). Orphanet J Rare Dis. 2017;12(1):50.","journal-title":"Orphanet J Rare Dis"},{"key":"2571_CR2","unstructured":"The European Parliament and the Council of the European Union. Regulation (EC) No. 141\/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Off J Eur Commun. 2000;L18\/1\u2013L18\/5."},{"key":"2571_CR3","unstructured":"US Food and Drug Administration (FDA): Orphan Drug Act. Public Law. 1983;97\u2013414."},{"key":"2571_CR4","unstructured":"European Commission. Joint evaluation of Regulation (EC) No 1901\/2006 on medicinal products for paediatric use and Regulation (EC) No 141\/2000 on orphan medicinal products. COMMISSION STAFF WORKING DOCUMENT. 2020;163 final(Part 1\/6)."},{"key":"2571_CR5","unstructured":"IQVIA in Statista. Percentage of orphan drugs approved by the EMA available to patients in Europe as of 2020, by country* [Graph]. 2021 [Available from: https:\/\/www.statista.com\/statistics\/1248698\/rate-of-orphan-drugs-availability-europe-by-country\/."},{"issue":"10","key":"2571_CR6","doi-asserted-by":"publisher","first-page":"e0140002","DOI":"10.1371\/journal.pone.0140002","volume":"10","author":"T Gammie","year":"2015","unstructured":"Gammie T, Lu CY, Babar ZU. Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries. PLoS ONE. 2015;10(10):e0140002.","journal-title":"PLoS ONE"},{"issue":"9629","key":"2571_CR7","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/S0140-6736(08)60873-9","volume":"371","author":"ME Haffner","year":"2008","unstructured":"Haffner ME, Torrent-Farnell J, Maher PD. Does orphan drug legislation really answer the needs of patients? Lancet. 2008;371(9629):2041\u20134.","journal-title":"Lancet"},{"key":"2571_CR8","unstructured":"America\u2019s Health Insurance Plans (AHIP): The Rise of Orphan Drugs 2019. Available from: https:\/\/www.ahip.org\/documents\/IB_OrphanDrugs-1004.pdf."},{"key":"2571_CR9","unstructured":"IQVIA. Orphan Drugs in the United States: Rare disease innovation and cost trends through 2019 2020 [Available from: https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports\/orphan-drugs-in-the-united-states-rare-disease-innovation-and-cost-trends-through-2019."},{"issue":"3","key":"2571_CR10","first-page":"83","volume":"1","author":"D Tordrup","year":"2014","unstructured":"Tordrup D, Tzouma V, Kanavos P. Orphan drug considerations in health technology assessment in eight European countries. Rare Dis Orphan Drugs. 2014;1(3):83\u201397.","journal-title":"Rare Dis Orphan Drugs"},{"issue":"2","key":"2571_CR11","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.healthpol.2017.03.009","volume":"123","author":"E Nicod","year":"2019","unstructured":"Nicod E, Annemans L, Bucsics A, Lee A, Upadhyaya S, Facey K. HTA programme response to the challenges of dealing with orphan medicinal products: process evaluation in selected European countries. Health Policy. 2019;123(2):140\u201351.","journal-title":"Health Policy"},{"issue":"1","key":"2571_CR12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s13023-019-1246-7","volume":"14","author":"J Mestre-Ferrandiz","year":"2019","unstructured":"Mestre-Ferrandiz J, Palaska C, Kelly T, Hutchings A, Parnaby A. An analysis of orphan medicine expenditure in Europe: is it sustainable? Orphanet J Rare Dis. 2019;14(1):287.","journal-title":"Orphanet J Rare Dis"},{"key":"2571_CR13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1750-1172-6-62","volume":"6","author":"C Schey","year":"2011","unstructured":"Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010\u20132020. Orphanet J Rare Dis. 2011;6:62.","journal-title":"Orphanet J Rare Dis"},{"key":"2571_CR14","doi-asserted-by":"publisher","first-page":"631527","DOI":"10.3389\/fphar.2021.631527","volume":"12","author":"A Blonda","year":"2021","unstructured":"Blonda A, Denier Y, Huys I, Simoens S. How to value orphan drugs? A review of European value assessment frameworks. Front Pharmacol. 2021;12:631527.","journal-title":"Front Pharmacol"},{"key":"2571_CR15","unstructured":"Agenzia Italiana del Farmaco (AIFA): Fondo Nazionale AIFA (\u201cFondo 5%\u201d) 2021. Available from: https:\/\/www.aifa.gov.it\/fondo-nazionale-aifa."},{"key":"2571_CR16","doi-asserted-by":"crossref","unstructured":"Aym\u00e9 S, Rodwell C: 2012 Report on the State of the Art of Rare Disease Activities in Europe of the European Union Committee of Experts on Rare Diseases: state of the art of rare disease activities in Italy 2012.","DOI":"10.1186\/1750-1172-7-S2-A1"},{"key":"2571_CR17","unstructured":"Agenzia Italiana del Farmaco (AIFA): Call AIFA 2018 for independent research on medicinal products 2018. Available from: https:\/\/www.aifa.gov.it\/documents\/20142\/0\/Call_AIFA_2018_Independent_Research.pdf."},{"key":"2571_CR18","unstructured":"Healthcare Financial Management Association (HFMA): Medicines costs in Scotland 2017 [Available from: https:\/\/www.hfma.org.uk\/docs\/default-source\/publications\/Briefings\/medicines-costs-in-scotland.pdf?sfvrsn=0."},{"key":"2571_CR19","unstructured":"Scottish Government. Review of Access to New Medicines: 3 Introduction 2016. Available from: https:\/\/www.gov.scot\/publications\/review-access-new-medicines\/pages\/3\/."},{"key":"2571_CR20","unstructured":"Scottish Government. Review of Access to New Medicines: 6.6 How NHS Boards are implementing SMC decisions under the new approach (both accepted and not recommended) including utilisation of the New Medicines Fund 2016 [Available from: https:\/\/www.gov.scot\/publications\/review-access-new-medicines\/pages\/3\/."},{"key":"2571_CR21","unstructured":"NHS England Cancer Drugs Fund Team: Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund) 2016. Available from: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2013\/04\/cdf-sop.pdf."},{"key":"2571_CR22","unstructured":"England N: Innovative Medicines Fund 2022. Available from: https:\/\/www.england.nhs.uk\/medicines-2\/innovative-medicines-fund\/#will-cancer-medicines-be-disadvantaged-by-the-creation-of-the-innovative-medicines-fund."},{"issue":"10","key":"2571_CR23","first-page":"508","volume":"25","author":"JD Chambers","year":"2019","unstructured":"Chambers JD, Panzer AD, Kim DD, Margaretos NM, Neumann PJ. Variation in US private health plans\u2019 coverage of orphan drugs. Am J Manag Care. 2019;25(10):508\u201312.","journal-title":"Am J Manag Care"},{"issue":"12","key":"2571_CR24","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.healthpol.2018.08.006","volume":"122","author":"M Charbonneau","year":"2018","unstructured":"Charbonneau M, Gagnon MA. Surviving niche busters: main strategies employed by Canadian private insurers facing the arrival of high cost specialty drugs. Health Policy. 2018;122(12):1295\u2013301.","journal-title":"Health Policy"},{"issue":"10044","key":"2571_CR25","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(16)30242-2","volume":"388","author":"D Montagu","year":"2016","unstructured":"Montagu D, Goodman C. Prohibit, constrain, encourage, or purchase: how should we engage with the private health-care sector? Lancet. 2016;388(10044):613\u201321.","journal-title":"Lancet"},{"issue":"8","key":"2571_CR26","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.healthpol.2019.05.021","volume":"123","author":"O Loblova","year":"2019","unstructured":"Loblova O, Csanadi M, Ozieranski P, Kalo Z, King L, McKee M. Patterns of alternative access: unpacking the Slovak extraordinary drug reimbursement regime 2012\u20132016. Health Policy. 2019;123(8):713\u201320.","journal-title":"Health Policy"},{"issue":"4","key":"2571_CR27","doi-asserted-by":"publisher","first-page":"244","DOI":"10.5582\/irdr.2016.01054","volume":"5","author":"G Balasubramanian","year":"2016","unstructured":"Balasubramanian G, Morampudi S, Chhabra P, Gowda A, Zomorodi B. An overview of compassionate use programs in the European Union member states. Intractable Rare Dis Res. 2016;5(4):244\u201354.","journal-title":"Intractable Rare Dis Res"},{"key":"2571_CR28","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13023-015-0306-x","volume":"10","author":"HI Hyry","year":"2015","unstructured":"Hyry HI, Manuel J, Cox TM, Roos JC. Compassionate use of orphan drugs. Orphanet J Rare Dis. 2015;10:100.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2571_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.therap.2018.12.002","volume":"74","author":"N Albin","year":"2019","unstructured":"Albin N, Chassagnol F, Bergmann JF, et al. Early access to health products in France: Major advances of the French \u201cConseil strategique des industries de sante\u201d (CSIS) to be implemented (modalities, regulations, funding). Therapie. 2019;74(1):103\u201317.","journal-title":"Therapie"},{"issue":"1","key":"2571_CR30","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13023-016-0507-y","volume":"11","author":"M Dooms","year":"2016","unstructured":"Dooms M, Cassiman D, Simoens S. Off-label use of orphan medicinal products: a Belgian qualitative study. Orphanet J Rare Dis. 2016;11(1):144.","journal-title":"Orphanet J Rare Dis"},{"key":"2571_CR31","unstructured":"Pharma.be: Zeldzame ziekten en weesgeneesmiddelen 2021. Available from: https:\/\/pharma.be\/nl\/expertise\/zeldzame-ziekten-en-weesgeneesmiddelen#:~:text=Concrete%20cijfers%20bevestigen%20deze%20stelling,1%20januari%202020%20werden%20terugbetaald."},{"key":"2571_CR32","unstructured":"Rijksinstituut voor ziekte-en invalideitsverzekering (RIZIV): Lijst van (wees)geneesmiddelen met college 2021. Available from: https:\/\/www.inami.fgov.be\/SiteCollectionDocuments\/lijst_weesgeneesmiddelen_colleges.pdf."},{"key":"2571_CR33","unstructured":"IQVIA: EFPIA patients W.A.I.T. Indicator 2020 Survey 2021. Available from: https:\/\/www.efpia.eu\/media\/602652\/efpia-patient-wait-indicator-final-250521.pdf."},{"key":"2571_CR34","unstructured":"Rijksinstituut voor ziekte- en invalideitsverzekering (RIZIV): Weesgeneesmiddelen 2021. Available from: https:\/\/www.inami.fgov.be\/nl\/themas\/kost-terugbetaling\/door-ziekenfonds\/geneesmiddel-gezondheidsproduct\/terugbetalen\/wees\/Paginas\/default.aspx."},{"key":"2571_CR35","unstructured":"Rijksinstituut voor ziekte- en invalideitsverzekering (RIZIV): Het Bijzonder solidariteitsfonds (BSF): uitzonderlijke vergoeding van medische verstrekkingen 2021. Available from: https:\/\/www.inami.fgov.be\/nl\/themas\/kost-terugbetaling\/door-ziekenfonds\/bijzonder-solidariteitsfonds\/Paginas\/default.aspx."},{"key":"2571_CR36","unstructured":"Guillaume, P., Moldenaers, I., Bult\u00e9, S., Debruyne, H., Devriese, S., Kohn, L., et al.: Optimalisatie van de werkingsprocessen van het Bijzonder Solidariteitsfonds. Health Services Research (HSR). Brussel: Federaal Kenniscentrum voor de Gezondheidszorg (KCE); 2010. Report No.: 133A."},{"key":"2571_CR37","unstructured":"Verzekeringen.be: Aanvullende ziekteverzekering 2021. Available from: https:\/\/www.verzekeringen.be\/alles-over-aanvullende-ziekteverzekeringen."},{"key":"2571_CR38","unstructured":"(KCE) BHCKC. Health Systems in Transition (HiT) : Belgium Health system Review 2020 [Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/339168\/HiT-22-5-2020-eng.pdf."},{"key":"2571_CR39","unstructured":"Pharma.be: Compassionate use en medical need programs 2021. Available from: https:\/\/pharma.be\/nl\/expertise\/compassionate-use-en-medical-need-programs."},{"key":"2571_CR40","unstructured":"Rijksinstituut voor ziekte- en invalideitsverzekering (RIZIV): Onbeantwoorde medische behoeften - Unmet Medical Need 2021 [Available from: https:\/\/www.riziv.fgov.be\/nl\/themas\/kost-terugbetaling\/door-ziekenfonds\/geneesmiddel-gezondheidsproduct\/terugbetalen\/Paginas\/unmet-medical-need.aspx#.WhgUoFWnGpo."},{"issue":"3","key":"2571_CR41","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.ijnurstu.2011.09.012","volume":"49","author":"BD de Casterle","year":"2012","unstructured":"de Casterle BD, Gastmans C, Bryon E, Denier Y. QUAGOL: a guide for qualitative data analysis. Int J Nurs Stud. 2012;49(3):360\u201371.","journal-title":"Int J Nurs Stud"},{"issue":"2","key":"2571_CR42","doi-asserted-by":"publisher","first-page":"594","DOI":"10.2307\/1959090","volume":"69","author":"J Harsanyi","year":"1975","unstructured":"Harsanyi J. Can the maximin principle serve as a basis for morality? A critique of John Rawls\u2019s theory. Am Polit Sci Rev. 1975;69(2):594\u2013606.","journal-title":"Am Polit Sci Rev"},{"key":"2571_CR43","unstructured":"Research and Markets. US Health and Medical Insurance Market to 2026: Leading insurers account for $130 Billion 2021. Available from: https:\/\/www.prnewswire.com\/news-releases\/us-health-and-medical-insurance-market-to-2026-leading-insurers-account-for-130-billion-301428975.html."},{"issue":"1","key":"2571_CR44","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1207\/s15327957pspr1001_3","volume":"10","author":"MG Haselton","year":"2006","unstructured":"Haselton MG, Nettle D. The paranoid optimist: an integrative evolutionary model of cognitive biases. Pers Soc Psychol Rev. 2006;10(1):47\u201366.","journal-title":"Pers Soc Psychol Rev"},{"key":"2571_CR45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/BF00055564","volume":"1","author":"W Samuelson","year":"1988","unstructured":"Samuelson W, Zeckhauser R. Status quo bias in decision making. J Risk Uncertainty. 1988;1:7\u201359.","journal-title":"J Risk Uncertainty"},{"key":"2571_CR46","unstructured":"Directorate-General for Research and Innovation (European Parliament): Health care systems in the EU: a comparative study, 1998. Available from: https:\/\/op.europa.eu\/en\/publication-detail\/-\/publication\/6125eac3-c1d3-4ea3-8f3d-9d9888d25e56."},{"key":"2571_CR47","unstructured":"CESifo DICE: Bismarck versus beveridge: social insurance systems in Europe 2008. Available from: https:\/\/www.ifo.de\/DocDL\/dicereport408-db6.pdf."},{"issue":"8","key":"2571_CR48","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s40264-021-01081-z","volume":"44","author":"CJ Jonker","year":"2021","unstructured":"Jonker CJ, de Vries ST, van den Berg HM, McGettigan P, Hoes AW, Mol PGM. Capturing data in rare disease registries to support regulatory decision making: a survey study among industry and other stakeholders. Drug Saf. 2021;44(8):853\u201361.","journal-title":"Drug Saf"},{"key":"2571_CR49","unstructured":"European Commission Working Group: Pooling data to combat rare diseases 2017. Available from: https:\/\/ec.europa.eu\/jrc\/en\/news\/pooling-data-combat-rare-diseases."},{"key":"2571_CR50","unstructured":"Trifork: Danish health data authority: the shared medication record 2007. Available from: https:\/\/trifork.com\/?portfolio=fmk."},{"key":"2571_CR51","unstructured":"Pharma Boardroom: In focus: Lisbeth Nielsen\u2014Director General, Danish Health Data Authority 2021. Available from: https:\/\/pharmaboardroom.com\/interviews\/lisbeth-nielsen-director-general-danish-health-data-authority\/."},{"key":"2571_CR52","unstructured":"International Horizon Scanning Initiative (IHSI): Belgium-based IHSI hails the start of a contract to supply the International Horizon Scanning Database 2021. Available from: https:\/\/ihsi-health.org\/2021\/belgium-based-ihsi-hails-the-start-of-a-contract-to-supply-the-international-horizon-scanning-database\/."},{"key":"2571_CR53","unstructured":"European Commission: EU Protects: how the EU connected experts to treat epilepsy 2018. Available from: https:\/\/audiovisual.ec.europa.eu\/en\/video\/I-164244."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02571-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02571-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02571-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T09:14:31Z","timestamp":1670577271000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02571-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2571"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02571-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,9]]},"assertion":[{"value":"15 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"\u201cThe Research Ethics Committee UZ\/KU Leuven hereby grants favorable advice to the proposed study, as it was described in the protocol. The Commission is of the opinion that from an ethical standpoint there are no objections to the proposed study. The study was approved on 09\u201309\u20132020.\u201d Committee\u2019s reference number: MP015702.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Steven Simoens (SS) has previously conducted research about market access of orphan drugs sponsored by the Belgian Health Care Knowledge Centre and by Genzyme (now Sanofi), and he has participated in an orphan drug roundtable sponsored by Celgene. SS is a member of the ISPOR Rare Disease Special Interest Group\u2019s Challenges in Research and Health Technology Assessment of Rare Disease Technologies Working Group, the International Working Group on Orphan Drugs, and the Innoval Working Group on Ultra-Rare Disorders. Kathleen Claes has received consultancy fees from Alexion, Astellas and Sanofi. Isabelle Huys reports no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"429"}}